Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 66 articles:
HTML format
Text format



Single Articles


    October 2018
  1. COTTU P, D'Hondt V, Dureau S, Lerebours F, et al
    Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.
    Ann Oncol. 2018 Oct 11. pii: 5126820. doi: 10.1093.
    PubMed     Text format     Abstract available


  2. BRANDAO M, Ignatiadis M
    CDK4/6 inhibitors as neoadjuvant treatment in breast cancer - what can we learn?
    Ann Oncol. 2018 Oct 10. pii: 5126228. doi: 10.1093.
    PubMed     Text format    


    September 2018
  3. SZEKELY B, Bossuyt V, Li X, Wali VB, et al
    Immunological differences between primary and metastatic breast cancer.
    Ann Oncol. 2018 Sep 10. pii: 5094494. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2018
  4. CHEN X, Li Y, Ouyang T, Li J, et al
    Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers.
    Ann Oncol. 2018 Aug 27. pii: 5079839. doi: 10.1093.
    PubMed     Text format     Abstract available


  5. ETTL J, Quek RGW, Lee KH, Rugo HS, et al
    Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
    Ann Oncol. 2018 Aug 15. pii: 5074207. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2018
  6. CARDOSO F, Senkus E, Costa A, Papadopoulos E, et al
    4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4).
    Ann Oncol. 2018 Jul 19. pii: 5055519. doi: 10.1093.
    PubMed     Text format    


  7. ROBSON M
    Selecting patients with triple negative breast cancer for platinum-based therapy: we still haven't found what we're looking for.
    Ann Oncol. 2018 Jul 4. pii: 5048958. doi: 10.1093.
    PubMed     Text format    


    June 2018
  8. BRUSSELAERS N, Tamimi RM, Konings P, Rosner B, et al
    Different menopausal hormone regimens and risk of breast cancer.
    Ann Oncol. 2018 Jun 18. pii: 5039890. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. DIOSSY M, Reiniger L, Sztupinszki Z, Krzystanek M, et al
    Breast cancer brain metastases show increased levels of genomic aberration based homologous recombination deficiency scores relative to their corresponding primary tumors.
    Ann Oncol. 2018 Jun 18. pii: 5039891. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. ZHANG J, Lin Y, Sun XJ, Wang BY, et al
    Biomarker assessment of the CBCSG006 trial: A randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
    Ann Oncol. 2018 Jun 14. pii: 5037891. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. IGNATIADIS M, Litiere S, Rothe F, Riethdorf S, et al
    Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial.
    Ann Oncol. 2018 Jun 11. pii: 5035683. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. MALORNI L, Curigliano G, Minisini AM, Cinieri S, et al
    Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.
    Ann Oncol. 2018 Jun 11. pii: 5035682. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. YARDLEY DA, Coleman R, Conte P, Cortes J, et al
    nab-Paclitaxel Plus Carboplatin or Gemcitabine vs Gemcitabine Plus Carboplatin as First-Line Treatment for Patients With Triple-Negative Metastatic Breast Cancer: Results From the tnAcity Trial.
    Ann Oncol. 2018 Jun 6. pii: 5033593. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. POGGIO F, Bruzzone M, Ceppi M, Ponde NF, et al
    Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    Ann Oncol. 2018 Jun 4. pii: 5026316. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2018
  15. CURIGLIANO G, Burstein HJ, Winer EP, Gnant M, et al
    De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
    Ann Oncol. 2018 May 3. pii: 4992289. doi: 10.1093.
    PubMed     Text format    


  16. GAGE MM, Mylander WC, Rosman M, Fujii T, et al
    Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay.
    Ann Oncol. 2018;29:1280-1285.
    PubMed     Text format     Abstract available


  17. LIU C, Wang L, Zhuang J, Liu L, et al
    Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis.
    Ann Oncol. 2018;29:1329-1330.
    PubMed     Text format    


    April 2018
  18. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Ann Oncol. 2018 Apr 27. pii: 4989216. doi: 10.1093.
    PubMed     Text format     Abstract available


  19. LOIBL S, Majewski I, Guarneri V, Nekljudova V, et al
    PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
    Ann Oncol. 2018 Apr 26. pii: 4986930. doi: 10.1093.
    PubMed     Text format    


  20. GEFFEN DB
    Should decisions on adding adjuvant chemotherapy in early stage ER positive breast cancer be based on gene expression testing or clinicopathologic factors or both?
    Ann Oncol. 2018 Apr 4. pii: 4959909. doi: 10.1093.
    PubMed     Text format    


  21. CRUZ C, Castroviejo-Bermejo M, Gutierrez-Enriquez S, Llop-Guevara A, et al
    RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer.
    Ann Oncol. 2018 Apr 4. pii: 4959904. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2018
  22. CORTES J, Perez-Garcia J, Levy C, Gomez Pardo P, et al
    Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer.
    Ann Oncol. 2018 Feb 21. pii: 4897992. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. MARTIN M, Campone M, Bondarenko I, Sakaeva D, et al
    Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
    Ann Oncol. 2018 Feb 10. pii: 4852792. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  24. TAN WW, Hillman DW, Salim M, Northfelt DW, et al
    N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.
    Ann Oncol. 2018 Jan 29. pii: 4829660. doi: 10.1093.
    PubMed     Text format    


  25. BARECHE Y, Venet D, Ignatiadis M, Aftimos P, et al
    Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
    Ann Oncol. 2018 Jan 22. pii: 4819112. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. HARTMAIER RJ, Trabucco SE, Priedigkeit N, Chung JH, et al
    Recurrent hyperactive ESR1 fusion proteins in endocrine therapy resistant breast cancer.
    Ann Oncol. 2018 Jan 19. pii: 4817340. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. ABBOSH C, Swanton C, Birkbak NJ
    Circulating tumor DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer.
    Ann Oncol. 2018 Jan 17. pii: 4815740. doi: 10.1093.
    PubMed     Text format    


  28. TURNER NC, Finn RS, Martin M, Im SA, et al
    Clinical Considerations of the Role of Palbociclib in the Management of Advanced Breast Cancer Patients With and Without Visceral Metastases.
    Ann Oncol. 2018 Jan 11. pii: 4802189. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. SOMASHEKHAR SP, Sepulveda MJ, Puglielli S, Norden AD, et al
    Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board.
    Ann Oncol. 2018 Jan 9. pii: 4781689. doi: 10.1093.
    PubMed     Text format     Abstract available


  30. SWAIN SM, Schneeweiss A, Gianni L, Gao JJ, et al
    Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
    Ann Oncol. 2018 Jan 2. pii: 4782676. doi: 10.1093.
    PubMed     Text format    


    December 2017
  31. KHOSROW-KHAVAR F, Yin H, Barkun A, Bouganim N, et al
    Aromatase Inhibitors and the Risk of Colorectal Cancer in Post-Menopausal Women with Breast Cancer.
    Ann Oncol. 2017 Dec 27. pii: 4779926. doi: 10.1093.
    PubMed     Text format     Abstract available


  32. SHARMA P, Barlow WE, Godwin AK, Pathak H, et al
    Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with doxorubicin-based adjuvant chemotherapy (SWOG S9313).
    Ann Oncol. 2017 Dec 23. pii: 4774220. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. SWAIN SM, Ewer MS, Viale G, Delaloge S, et al
    Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
    Ann Oncol. 2017 Dec 15. pii: 4748818. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. CONDORELLI R, Spring L, O'Shaughnessy J, Lacroix L, et al
    Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
    Ann Oncol. 2017 Dec 11. pii: 4725051. doi: 10.1093.
    PubMed     Text format     Abstract available


  35. GENNARI A, Sun Z, Hasler-Strub U, Colleoni M, et al
    A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.
    Ann Oncol. 2017 Dec 8. pii: 4710349. doi: 10.1093.
    PubMed     Text format     Abstract available


  36. PALUCH-SHIMON S, Peccatori FA
    BRCA 1 and 2 mutation status: the elephant in the room during oncofertility counseling for young breast cancer patients.
    Ann Oncol. 2017 Dec 5. pii: 4693825. doi: 10.1093.
    PubMed     Text format    


    November 2017
  37. FRANCIS PA
    Male Breast Cancer: Pink Ribbon Blues.
    Ann Oncol. 2017 Nov 20. doi: 10.1093.
    PubMed     Text format    


  38. BUISSERET L, Pommey S, Allard B, Garaud S, et al
    Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
    Ann Oncol. 2017 Nov 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. SESTAK I, Smith SG, Howell A, Forbes JF, et al
    Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
    Ann Oncol. 2017 Nov 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  40. PATEL R, Maxwell S, Yan D, Dressler EV, et al
    Medical Oncologists' Perception of Anti-Estrogen Therapy Benefit in Premenopausal Women with Hormone Receptor-Positive Early Breast Cancer.
    Ann Oncol. 2017 Nov 2. doi: 10.1093.
    PubMed     Text format    


    October 2017
  41. KOK M
    LAG-3: another brake to release in breast cancer?
    Ann Oncol. 2017 Oct 30. doi: 10.1093.
    PubMed     Text format    


  42. CARDOSO F, Bartlett JMS, Slaets L, van Deurzen CHM, et al
    Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
    Ann Oncol. 2017 Oct 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  43. BLACKWELL K, Gascon P, Krendyukov A, Gattu S, et al
    Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase 3, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppr
    Ann Oncol. 2017 Oct 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  44. CRISCITIELLO C, Bayar MA, Curigliano G, Symmans FW, et al
    A gene signature to predict high tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer.
    Ann Oncol. 2017 Oct 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  45. MOBUS V, Jackisch C, Lueck HJ, du Bois A, et al
    Ten-year Results of Intense Dose-dense chemotherapy show superior survival compared to a conventional schedule in High-risk Primary Breast Cancer: Final results of AGO Phase III iddEPC trial.
    Ann Oncol. 2017 Oct 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  46. NUCIFORO P, Pascual T, Cortes J, Llombart-Cussac A, et al
    A predictive model of pathological response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
    Ann Oncol. 2017 Oct 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  47. NABIEVA N, Kellner S, Fehm T, Haberle L, et al
    Patient and tumor characteristics and their influence on early therapy persistence with letrozole in postmenopausal patients with early breast cancer.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  48. LAMBERTINI M, Goldrat O, Ferreira AR, Dechene J, et al
    Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  49. FRIBBENS C, Garcia Murillas I, Beaney M, Hrebien S, et al
    Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
    Ann Oncol. 2017 Oct 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  50. FUJII T, Kogawa T, Dong W, Sahin AA, et al
    Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer.
    Ann Oncol. 2017;28:2420-2428.
    PubMed     Text format     Abstract available


    September 2017
  51. HAN HS, Dieras V, Robson M, Palacova M, et al
    Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study.
    Ann Oncol. 2017 Sep 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  52. BURUGU S, Gao D, Leung S, Chia SK, et al
    LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.
    Ann Oncol. 2017 Sep 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  53. CURIGLIANO G, Burstein HJ, Winer EP, Gnant M, et al
    Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al.
    Ann Oncol. 2017 Sep 25. doi: 10.1093.
    PubMed     Text format    


  54. KIROVA YM, Carroll S, Fourquet A, Offersen B, et al
    The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology.
    Ann Oncol. 2017 Sep 22. doi: 10.1093.
    PubMed     Text format    


  55. CHAJES V, Assi N, Biessy C, Ferrari P, et al
    A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  56. MESSINA C, Messina M, Zanardi E
    Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format    


  57. BUTTERBAUGH ST, Patel R, Romond EH, Mathew A, et al
    Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: To continue or not to continue.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format    


  58. NITZ UA, Gluz O, Christgen M, Grischke EM, et al
    De-escalation strategies in HER2-positive early breast cancer (EBC): Final analysis of the WSG-ADAPT HER2+/HR- phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekl
    Ann Oncol. 2017 Sep 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  59. REGAN MM, Walley BA, Francis PA, Fleming GF, et al
    Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
    Ann Oncol. 2017;28:2225-2232.
    PubMed     Text format     Abstract available


  60. HAMY AS, Pierga JY, Sabaila A, Laas E, et al
    Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.
    Ann Oncol. 2017;28:2233-2240.
    PubMed     Text format     Abstract available


  61. BERNICHON E, Vallard A, Wang Q, Attignon V, et al
    Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol.
    Ann Oncol. 2017 Sep 1. doi: 10.1093.
    PubMed     Text format     Abstract available


  62. VAN BOCKSTAL M, Libbrecht L, Floris G, Lambein K, et al
    Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma?
    Ann Oncol. 2017;28:2317.
    PubMed     Text format    


    August 2017
  63. CHUNG JH, Pavlick D, Hartmaier R, Schrock AB, et al
    Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
    Ann Oncol. 2017 Aug 31. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  64. PRUNERI G, Lazzeroni M, Bagnardi V, Tiburzio GB, et al
    The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.
    Ann Oncol. 2017;28:321-328.
    PubMed     Text format     Abstract available


  65. YANG TO, Cairns BJ, Reeves GK, Green J, et al
    Cancer risk among 21st century blood transfusion recipients.
    Ann Oncol. 2017;28:393-399.
    PubMed     Text format     Abstract available


  66. MAKKOUK A, Sundaram V, Chester C, Chang S, et al
    Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy.
    Ann Oncol. 2017;28:415-420.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: